Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 4/20 | 0.41 |
| ▸ | EDNRB | P24530 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8627743 | 0.94 | EDNRA (0.40) | EDNRAEDNRBSCN9A | |
| SCHEMBL7653814 | 0.86 | EDNRA (0.41) | EDNRAEDNRB | |
| SCHEMBL7653881 | 0.79 | EDNRA (0.51) | EDNRAEDNRB | |
| SCHEMBL7814457 | 0.79 | EDNRA (0.50) | EDNRAEDNRB | |
| SCHEMBL7659658 | 0.76 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL7659653 | 0.76 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL9543742 | 0.73 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL7533979 | 0.73 | EDNRA (0.55) | EDNRAEDNRB | |
| SCHEMBL9543747 | 0.73 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL7653068 | 0.72 | EDNRA (0.51) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448260-B2 | 3-(2-CARBOXYMETHOXY-4-METHOXYPHENYL)-1-(3,4-METHYLENEDIOXY -PHENYL)-5-(PROP-1-YLOXY)-INDANE-2-CARBOXYLIC ACID AS AN ESPECIALLY PREFERRED COMPOUND; HYPOTENSIVE AGENTS; CARDIOVASCULAR, UROGENITAL AND RESPIRATORY DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| US-6274737-B1 | CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-08-14 | — | — | US | disclosed |
| US-6271399-B1 | METHYL 3-(3,4-METHYLENEDIOXYPHENYL)-6-(PROP-1-YLOXY)-INDANE-2-CARBOXYLATE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-08-07 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| US-5719183-A | HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5716985-A | INDANE AND INDENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| US-5716984-A | INDANE AND INDENE DERIVATIVES; TREATMENT OF CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885SCN9A 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.